← Back

Wire · opportunities

Korean drugmaker Yuhan wins trial approval for kidney disease candidate

Published

16 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

South Korea

◆ Source

Read at thepharmanews.net →

◆ Verified

Fusion42 · 16 November 2026 · Fusion42 review

South Korea's Ministry of Food and Drug Safety approved a Phase 1 trial for Yuhan's YH34180, a small-molecule oral drug candidate aimed at treating chronic kidney disease by targeting inflammation and fibrosis pathways.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a clearer window to enter the Korean chronic kidney disease drug market as local regulator greenlights first-in-human trials for novel compounds targeting unmet needs in inflammation and fibrosis.

◆ Coverage

1 source · 16 Nov 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialkidney-diseasedrug-developmentsouth-koreabiotech